Figure 2.
The spectrum of hematological malignancies. (A) The spectrum of hematological malignancies in the entire cohort (202 patients). (B) The differential tumor spectrum in patients with absent ATM kinase activity and in those with residual ATM kinase activity. Patients with absent ATM kinase activity (n = 82): lymphoblastic leukemia/lymphoma (34%), mature B-cell lymphoma (49%), HL (13%), and other (4%). Patients with residual ATM kinase activity (n = 27): lymphoblastic leukemia/lymphoma (82%), mature B-cell lymphoma (7%), HL (7%), and other (4%). ALCL, anaplastic large cell lymphoma; AML, acute myeloid leukemia; DLBCL, diffuse large B-cell lymphoma; HL, Hodgkin lymphoma; LBL, lymphoblastic lymphoma; LPD, lymphoproliferative disorder; LYG, lymphomatous granulomatosis; PTCL, peripheral T-cell lymphoma; T-PLL, T-cell prolymphocytic leukemia.

The spectrum of hematological malignancies. (A) The spectrum of hematological malignancies in the entire cohort (202 patients). (B) The differential tumor spectrum in patients with absent ATM kinase activity and in those with residual ATM kinase activity. Patients with absent ATM kinase activity (n = 82): lymphoblastic leukemia/lymphoma (34%), mature B-cell lymphoma (49%), HL (13%), and other (4%). Patients with residual ATM kinase activity (n = 27): lymphoblastic leukemia/lymphoma (82%), mature B-cell lymphoma (7%), HL (7%), and other (4%). ALCL, anaplastic large cell lymphoma; AML, acute myeloid leukemia; DLBCL, diffuse large B-cell lymphoma; HL, Hodgkin lymphoma; LBL, lymphoblastic lymphoma; LPD, lymphoproliferative disorder; LYG, lymphomatous granulomatosis; PTCL, peripheral T-cell lymphoma; T-PLL, T-cell prolymphocytic leukemia.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal